Craig-Hallum Maintains Buy on Akoya Biosciences, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Bill Bonello maintains a Buy rating on Akoya Biosciences (NASDAQ:AKYA) but lowers the price target from $7.5 to $7.

August 06, 2024 | 2:52 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Craig-Hallum analyst Bill Bonello maintains a Buy rating on Akoya Biosciences but lowers the price target from $7.5 to $7.
The Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates a more cautious outlook on its short-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100